Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2020

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation

Published 11 March 2020
Categorized as 2020, BT-001, Publication

Major R&D milestones achieved in 2019 and strong clinical activity in 2020

20200311 Resultats 2019 EN

Published 11 March 2020
Categorized as 2020, Press release

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

20200303 BT-001 presentations EN

Published 3 March 2020
Categorized as 2020, BT-001, Press release

First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases

20200220 PR FPI 6002.03 EN

Published 20 February 2020
Categorized as 2020, Press release, TG6002

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdfClémentine Spring-Giusti et al.American College of Toxicology – 40th Annual MeetingDownload the poster herePoster Presentation

Published 22 January 2020
Categorized as -others, 2020, Publication

Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

20200107 PR TG4050 FPI – EN

Published 7 January 2020
Categorized as 2020, Press release, TG4050

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation

Published 17 November 2019
Categorized as -others, 2020, Publication

Posts pagination

Newer posts Page 1 … Page 5
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu